Anavex life sciences announces u.s. phase 2 clinical trial of anavex®3-71 in schizophrenia

Placebo-controlled phase 2 trial cleared by the fda – trial to begin in q2 2024 trial to include schizophrenia validated clinical outcomes panss and eeg/erp biomarkers trial to study positive, negative, and cognitive domains of schizophrenia based on anavex®3-71's ability to synergistically activate both sigmar1 and m1 muscarinic receptors new york, jan. 16, 2024 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including alzheimer's disease, parkinson's disease, rett syndrome, and schizophrenia, today announced the initiation of the u.s. fda cleared placebo-controlled phase 2 trial of anavex®3-71 for the treatment of schizophrenia, which is expected to begin in q2 2024. anavex®3-71 positive initial phase 1 results in healthy volunteers were previously reported.1 anavex®3-71 (formerly af710b) is a dual sigmar1 receptor agonist and m1 positive allosteric modulator with agonistic effects.
AVXL Ratings Summary
AVXL Quant Ranking